News	Drug Formulary	Safety Net	Resources
	Drug Formulary Categories and Charges Search HA Drug Formulary Self-financed Drugs Available for Purchase by Patients at HA Pharmacy How we evaluate new drugs Governance Drug Management Committee Drug Advisory Committee Drug Formulary Committee Drug & Therapeutics Committee Drug Selection Committee Expert Panel Medication Safety Committee	Samaritan Fund Community Care Fund	Drug Education HA Drug Formulary Management Manual Frequently Asked Questions Useful Links

DAC Meeting Outcome

DAC Meeting Outcome - Jul 2023

	Generic name	Brand name	Therapeutic Class	Meeting outcome	Primary reason for rejection¹
1	Abemaciclib	Verzenio	Malignant disease and immunosuppression	Rejected	The justification of the treatment’s cost in relation to its benefits is insufficient
2	Albutrepenonacog alfa	Idelvion	Cardiovascular system	Rejected	The justification of the treatment’s cost in relation to its benefits is insufficient
3	Anifrolumab	Saphnelo	Musculoskeletal and joint disease	Pending	Pending further information
4	Avalglucosidase alfa	Nexviazyme	Nutrition and blood	Approved
5	Darolutamide	Nubeqa	Malignant disease and immunosuppression	Rejected	Insufficient evidence to demonstrate significant clinical outcome benefits
6	Dupilumab	Dupixent	Skin	Approved
7	Faricimab	Vabysmo	Eye	Approved
8	Febuxostat	Feburic	Musculoskeletal and joint disease	Approved
9	Finerenone	Kerendia	Cardiovascular system	Approved
10	Infliximab	Remsima	Gastro-intestinal system	Approved
11	Insulin glargine	Toujeo	Endocrine system	Pending	Pending further information
12	Lenvatinib / Pembrolizumab	Lenvima / Keytruda	Malignant disease and immunosuppression	Approved
13	Luspatercept	Reblozyl	Nutrition and blood	Approved
14	Paclitaxel albumin	Abraxane	Malignant disease and immunosuppression	Approved
15	Pembrolizumab	Keytruda	Malignant disease and immunosuppression	Approved
16	Ripretinib	Qinlock	Malignant disease and immunosuppression	Rejected	The justification of the treatment’s cost in relation to its benefits is insufficient
17	Risankizumab	Skyrizi	Musculoskeletal and joint disease	Approved
18	Ruxolitinib	Jakavi	Malignant disease and immunosuppression	Approved
19	Sotorasib	Lumakras	Malignant disease and immunosuppression	Rejected	Insufficient evidence to demonstrate significant clinical outcome benefits
20	Tisagenlecleucel	Kymriah	Malignant disease and immunosuppression	Pending	Pending further information
21	Trastuzumab	Herzuma	Malignant disease and immunosuppression	Pending	Pending further information
22	Trastuzumab Deruxtecan	Enhertu	Malignant disease and immunosuppression	Approved
23	Tucatinib	Tukysa	Malignant disease and immunosuppression	Rejected	The justification of the treatment’s cost in relation to its benefits is insufficient
24	Zanubrutinib	Brukinsa	Malignant disease and immunosuppression	Approved